- Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data
- Additional data include new Phase 3 RISE and SHINE analyses demonstrating no new or unexpected safety concerns in young adults with schizophrenia treated with UZEDY
- Global ADVANCE survey findings also reveal real-world experiences and perspectives on long-acting injectable... (continue reading...)
- Nearly 98% of patients experience quality of life impact as a result of tardive dyskinesia (TD) including social, psychological, physical and recreational aspects of daily living
- Data highlight for the first time that TD has a multidimensional impact on patients including those with mild TD severity
- IMPACT-TD Registry is the largest-ever study of its kind evaluating the holistic effects of TD over three years along with real-world treatment patterns and outcomes... (continue reading...)
- Study shows that FPM data can be reliably and quickly generated even through minimally invasive small-needle biopsies, which may expand the accessibility of FPM to provide personalized treatment validation and recommendations.
- NIMHD-funded study explores the relationship between biomarkers and racial/ethnic differences in response to cancer therapies to address existing health disparities.
- New research builds on a body of clinical evidence published in the... (continue reading...)
OSAKA, Japan--(BUSINESS WIRE)-- The city of Tondabayashi in Osaka is excited to announce a new inbound tour by "SABIWabisabi," aimed at revitalizing the local community. This exclusive tour combines traditional Japanese cultural experiences with gourmet meals using premium ingredients, all set in a historic Japanese house. Reservations open on June 1, 2024.
This press release features multimedia. View the full release here: ... (continue reading...)
CHICAGO--(BUSINESS WIRE)-- Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the delivery of guideline-directed biomarker testing for patients with non-small cell lung cancer (NSCLC). The magnitude and frequency of updates to oncology guidelines each year make it difficult for the updates to be rapidly... (continue reading...)
More Business Wire
View Older Stories-
Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
-
Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
-
Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
-
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual
-
Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
-
Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
-
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
-
Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
-
Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
-
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
-
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
-
Clariane: Information on the Availability of an Amendment to the 2023 Universal Registration Document
-
AnalytixInsight Reports 2023 Financial Results and Provides MCTO Status Update
-
The Chemours Company Temporarily Pauses Titanium Dioxide Production at Altamira, Mexico Site Amid Severe Regional Drought
-
Generation Mining Files Final Base Shelf Prospectus and Updates Shareholders
-
Tikehau Capital: Disclosure of shares repurchases from 24 May 2024 to 30 May 2024
-
Government Regulation Creates Blue Oceans
-
Inocras Presents Poster for Breast Cancer at 2024 ASCO Annual Meeting, Showing Transformative Impact of WGS-based HRD Testing
-
Leading Independent Proxy Advisory Firm Institutional Shareholder Services Joins Glass Lewis in Recommending Votes “FOR” ALL Nine WisdomTree Board Nominees
-
BRW Announces Notification of Sources of Distributions
-
SABA Announces Notification of Sources of Distributions
-
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Che
-
FCPT Announces Acquisition of a Mavis Tire Property for $2.4 Million
-
University of Phoenix and Executive Networks Study on Workplace Well-Being Highlights Challenges of Current Approaches in Addressing Mental Health
-
Capstone Copper Announces Retirement of Robert Gallagher from the Board of Directors
-
Drive Shack Inc. Releases Fourth Quarter and Full-Year 2023 Financial Results
-
Medical Properties Trust Publishes Its Third Annual Corporate Responsibility Report
-
FCPT Announces Acquisition of a National Veterinary Associates Property for $2.0 Million
-
Fonon's Additive Manufacturing Technology To Transform Construction Industry
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
Ventas to Present at Nareit’s REITweek 2024 Investor Conference
-
Korn Ferry Recognized for Seventh Consecutive Year as a Leader in Everest Group’s Recruitment Process Outsourcing (RPO) Services PEAK Matrix® Assessment 2024
-
Boston Omaha Corporation Announces Date for 2024 Annual Meeting of Stockholders
-
Darwin’s Natural Pet Products Continues Ongoing Partnership with PAWS for Annual PAWS Walk
-
Ault Disruptive Technologies Responds to Unusual Market Activity
-
Hope Biosciences Research Foundation Announces Topline Results of Cell Therapy Clinical Trial in Long COVID
-
State Street Corporation (NYSE: STT) Announces Date for Release of Second-Quarter 2024 Financial Results and Conference Call Webcast
-
MedX Health Corp. announces proposed extension of Non-brokered Private Placement offering
-
SITE Centers Declares Second Quarter 2024 Class A Preferred Share Dividend
-
Equity Residential to Participate in Nareit REITweek Conference
-
UBS Announces Assumption of Three Outstanding Credit Suisse ETNs; Rebranding as “ETRACS”
-
Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
-
PulteGroup, Inc. Announces Pricing for Tender Offers for Senior Notes
-
Bradley E. Cooper Appointed to Hamilton Board of Directors
-
Eaton Expands Reach into European Data Center Market by Making Strategic Investment in NordicEPOD
-
Westlake Chemical Partners Provides Tax Reporting Information
-
Camden Property Trust Announces Participation in Nareit’s REITweek 2024 Investor Conference and Provides Second Quarter 2024 Operating Update
-
Pacific Coast Oil Trust Announces There Will Be No May Cash Distribution
-
AvalonBay Communities, Inc. Announces Participation in Nareit’s REITweek Conference, Provides Second Quarter 2024 Operating Update, and Publishes Updated Investor Presentation